ArriVent BioPharma (AVBP) Operating Expenses (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Operating Expenses data on file, last reported at $46.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 30.94% year-over-year to $46.1 million; the trailing twelve-month figure through Mar 2026 stood at $156.9 million (up 11.73% YoY), and the FY2025 full-year result was $177.5 million, up 88.25% from the prior year.
• Operating Expenses grew to $46.1 million in Q1 2026, from $38.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $66.8 million in Q1 2025 to a low of $12.2 million in Q1 2023.
• A 4-year average of $30.2 million and a median of $24.2 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 222.98% in 2025 and slumped 30.94% in 2026, its largest moves.
• Tracing AVBP's Operating Expenses over 4 years: stood at $23.1 million in 2023, then rose by 2.54% to $23.7 million in 2024, then surged by 63.78% to $38.8 million in 2025, then advanced by 18.77% to $46.1 million in 2026.
• Business Quant data shows AVBP's Operating Expenses at $46.1 million in Q1 2026, $38.8 million in Q4 2025, and $38.3 million in Q3 2025.